ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

  • Abstract Number: 1153 • ACR Convergence 2023

    Unmasking SAPHO: A Case Series Revealing the Clinical Spectrum and Treatment Approaches

    Manush Sondhi1, Warda Maqsood2 and Sarwat Umer3, 1Louisiana State University, Shreveport, LA, 2LSU Health Science Center, Shreveport, LA, 3LSU Health Shreveport, Shreveport, LA

    Background/Purpose: SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) is a relatively rare and often underdiagnosed inflammatory disorder. Its diagnosis can be challenging due to its…
  • Abstract Number: 0126 • ACR Convergence 2023

    Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population

    Vladimir Liarski, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) - comprising polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) - is rare and difficult to study. We sought…
  • Abstract Number: 1656 • ACR Convergence 2023

    Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)

    anna Fryxelius1, Amy Martinsen2, Ida Løchting3, Linda Aimee Hartford Kvæl4, Astrid Lunestad2, Astrid Bergland4 and Kjersti Storheim2, 1Norwegian Rheumatism Association / REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, 4OsloMET, Oslo, Norway

    Background/Purpose: Patient and public involvement (PPI) is gaining increasing recognition as important to ensure research is relevant and to reduce avoidable research waste. Active collaboration…
  • Abstract Number: 0252 • ACR Convergence 2023

    Characterizing Granulomatous Mastitis: A Retrospective, Single-Institutional Case Series of a Racially and Ethnically Diverse Cohort

    Lindsay Pattison1, Bibi Ayesha2, Anand Kumthekar3, Maureen McEvoy2, Beth McLellan2 and Inessa Gendlina2, 1Albert Einstein College of Medicine, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Granulomatous mastitis (GM) is a rare, chronic, inflammatory breast condition characterized by granulomatous inflammation affecting mainly minority women of childbearing age. Patients present with…
  • Abstract Number: 1806 • ACR Convergence 2023

    The Prevalence of Cardiac Sarcoidosis – A Systemic Review and Meta-Analysis

    Daming Shao1, Jiyoung Seo1, Shaunak Mangeshkar1, Natalia Nazarenko1, Stepan Esagian1, Leonidas Palaiodimos1 and Damianos Kokkinidis2, 1Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, 2Yale University School of Medicine, New Haven, CT

    Background/Purpose: Cardiac sarcoidosis (CS) results from granulomatous infiltrating of the myocardium and manifests as an extended clinical spectrum from silence to conduction disturbances, ventricular tachyarrhythmias,…
  • Abstract Number: 0262 • ACR Convergence 2023

    Destructive Arthritis in Whipple Disease. a Single-center Case Series of 14 Patients

    Xavier Puéchal1, Philippe Blanche2, Olivier Fogel3, Omar Al Tabaa4, Roba Ghossan4, Xavier Ayral4, Jerome AVOUAC5, Maxime Breban6 and Yannick ALLANORE7, 1National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 2Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 3HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 4Department of Rheumatology, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 5Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 6Department of Rheumatology, Boulogne-Billancourt, France, 7Université Paris Cité, Paris, France

    Background/Purpose: Whipple disease is a chronic, curable, systemic bacterial infection caused by Tropheryma whipplei. The classic form usually begins with recurrent arthritis, followed years later…
  • Abstract Number: 1851 • ACR Convergence 2023

    Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

    Chiara Gasteiger1, Maria Lobo2, Lun Shen Wong1, Rachel Murdoch1 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand

    Background/Purpose: Transitioning patients with rheumatic diseases to biosimilars has become common to reduce healthcare costs and improve patient access to biologic therapies. However, it is…
  • Abstract Number: 0263 • ACR Convergence 2023

    Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease

    Taylor Koenig1, David Fell1, Danny Mammo1, Chao Zhang2, Sunil Srivastava1, Careen Lowder1, Sumit Sharma1 and Rula Hajj-Ali1, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Noninfectious inflammatory eye disease (NIIED) is a sight-threatening condition with two-thirds of patients incurring prolonged vision loss due to uncontrolled ocular inflammation. Non-glucocorticoid systemic…
  • Abstract Number: 1921 • ACR Convergence 2023

    Clinical Spectrum of VEXAS Syndrome in a Rheumatology Department

    Herman Mann1, Blanka Stiburkova2, Katerina Pavelcova1, Monika Belickova3, Cyril Salek3, Jana Juhaszova1 and Jiri Vencovsky4, 1Institute of Rheumatology, Praha 2, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Hematology and Blood Transfusion, Praha 2, Czech Republic, 4Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: VEXAS (vacuoles, E1 activating enzyme, X-linked, auto-inflammatory, somatic) syndrome is a clinically serious and potentially fatal adult-onset disease caused by somatic mutations in the…
  • Abstract Number: 0270 • ACR Convergence 2023

    Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety

    Tomohiro Koga1, Remi Sumiyoshi1, Yoshika Tsuji1, Ken Kodama2, Kaori Furukawa1, Yushiro Endo1 and Atsushi Kawakami3, 1Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, 2Neophama Japan, Tokyo, Japan, 3Nagasaki University, Nagasaki, Japan

    Background/Purpose: The primary objective of this study is to elucidate the therapeutic potential of 5-aminolevulinic acid/sodium ferrous citrate (5-ALA/SFC) in ameliorating the pathological manifestations associated…
  • Abstract Number: 1924 • ACR Convergence 2023

    Impact of the COVID-19 Pandemic on Clinical and Psychosocial Features of Patients with UCTD

    Caroline Siegel1, Lucy Masto1, Amaya Smole1, Bessie Stamm1, JoAnn Vega1, Dongmei Sun1, Deanna Jannat-Khah1, Michael Lockshin2, Lisa Sammaritano2 and Medha Barbhaiya2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: The early COVID-19 pandemic led to physical and psychological burdens for patients with systemic rheumatic diseases, whether or not they had had COVID-19. To…
  • Abstract Number: 0272 • ACR Convergence 2023

    Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study

    Marion Peyre1, Arthur Mageau1, Marie-cecile Henry Feugeas2, Serge Doan2, Caroline Halimi2, Isabelle Klein3, Tiphaine Goulenok2, Chrystelle Francois2, Marie-Paule Chauveheid2, Thomas Papo1 and Karim Sacre1, 1Université Paris Cité, Paris, France, 2Assistance Publique Hopitaux de Paris, Paris, France, 3Clinique Alleray-Labrouste, Paris, France

    Background/Purpose: Susac syndrome (SuS) is a rare vasculitis affecting the brain, retina and inner ear in young women. Nonreversible hearing loss is the main long-term…
  • Abstract Number: 1931 • ACR Convergence 2023

    Anti-Ku Antibodies: A Case Series

    Raquel Ugena García1, Cristina Calomarde Gomez1, Joan Climent2 and Lourdes Mateo Soria2, 1Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital Germans Trias i Pujol, Badalona, Spain

    Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
  • Abstract Number: 0281 • ACR Convergence 2023

    Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?

    Kristin Schmiedeberg1, Anna-Lena Walter1, Lukas Joos1, Martin Brutsche1, Johannes von Kempis2 and Andrea Rubbert-Roth1, 1Cantonal Hospital St. Gallen, St. Gallen, Switzerland, 2Kantonsspital St. Gallen, Division of rheumatology and immunology, St. Gallen, Switzerland

    Background/Purpose: Cystic fibrosis (CF) is characterized by mutations within the CFTR (cystic fibrosis transmembrane conductance regulator) gene that result in a defect of the chloride…
  • Abstract Number: 1940 • ACR Convergence 2023

    A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features

    Tegveer Sandhu1, Lea Meir2, Nicole Ng1, Lila Klein1, Jigna Zatakia1, Maria Padilla1 and Ioannis Tassiulas1, 1Icahn School of Medicine at Mount Sinai, New York, NY, 2Icahn School of Medicine, New York, NY

    Background/Purpose: Patients with interstitial lung diseases (ILD) and clinical features of autoimmunity who do not satisfy the classification criteria for a specific autoimmune rheumatic disease…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology